Pfizer Q4 FY16 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Pfizer management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Pfizer management said on order book — free account, 30 seconds.
Capex plans
Track Pfizer — get its next earnings analysis in your feed
How does Pfizer rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Pfizer rank in Pharmaceuticals & Biotechnology?
Compare Pfizer against every Pharmaceuticals & Biotechnology company (Q4 FY16) on revenue, margins and earnings-call signals.
Continue your research
What Pfizer's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q2 FY27)
4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect
- Sakar Healthcare Ltd (Q2 FY27)
2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se
- Dr Reddys Laboratories Ltd (Q2 FY27)
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.